AstraZeneca: Tagrisso approved in China for NSCLC

(CercleFinance.com) - AstraZeneca announces that its Tagrisso (osimertinib), combined with pemetrexed and platinum-based chemotherapy, has been approved in China for the first-line treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR mutations.


This approval is based on the results of a Phase III trial showing that this combination reduced the risk of disease progression or death by 38% compared with Tagrisso monotherapy.

Median progression-free survival (PFS) was 25.5 months with the combination, compared with 16.7 months with monotherapy.

This approval confirms the importance of Tagrisso as a primary treatment for EGFR-mutated lung cancer, either as monotherapy or with chemotherapy, particularly in Asia and China, AstraZeneca said.


Copyright (c) 2024 CercleFinance.com. All rights reserved.